Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

167.55 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

56 57 Next >

Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential ↗

December 14, 2023

The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight.

Via InvestorPlace

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

December 14, 2023

From Sage Therapeutics, Inc.

Via Business Wire

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

December 14, 2023

From Biogen Inc.

Via GlobeNewswire

Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry ↗

December 13, 2023

Via Benzinga

$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today ↗

December 11, 2023

Via Benzinga

The Latest Analyst Ratings for Biogen ↗

December 07, 2023

Via Benzinga

Comparative Study: Biogen And Industry Competitors In Biotechnology Industry ↗

November 28, 2023

Via Benzinga

Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today ↗

November 16, 2023

Via Benzinga

Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout ↗

December 12, 2023

While the market continues towards making new highs, it is falling short of making a breakout rally. Forthcoming CPI data and the upcoming FOMC meeting may be the catalyst for same.

Via Talk Markets

Biotech Is Coming Back, Can The Run Last? ↗

December 11, 2023

The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.

Via Talk Markets

December 09, 2023

These stocks aren't worth the risk.

Via The Motley Fool

S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets ↗

December 07, 2023

Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%).

Via Benzinga

Topics Stocks

Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry ↗

November 14, 2023

Via Benzinga

Expert Ratings for Biogen ↗

November 09, 2023

Via Benzinga

Why This Biogen Analyst Is Turning Bullish On Alzheimer's Treatment Prospects ↗

December 07, 2023

Biogen Inc (NASDAQ: BIIB) has been in focus due to its treatment for early-stage Alzheimer’s disease.

Via Benzinga

Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

December 04, 2023

No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.

Via MarketBeat

Topics Bonds

Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others ↗

November 21, 2023

Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this

Via Benzinga

Looking Into Biogen's Recent Short Interest ↗

November 06, 2023

Via Benzinga

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning ↗

November 17, 2023

Biotech companies are edging closer to finding the answers behind Alzheimer's disease.

Via Investor's Business Daily

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗

November 10, 2023

The major indexes ended long win streaks. Datadog led earnings winners.

Via Investor's Business Daily

The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? ↗

November 10, 2023

The real competitive battle is about to begin, and it will last a long time.

Via The Motley Fool

These Analysts Revise Their Forecasts On Biogen After Q3 Results ↗

November 09, 2023

Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings.

Via Benzinga

Thoughts For Thursday: Staying On Top - Barely ↗

November 09, 2023

The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago.

Via Talk Markets

Biogen (BIIB) Q3 2023 Earnings Call Transcript ↗

November 08, 2023

BIIB earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides ↗

November 08, 2023

Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the con

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 08, 2023

Via Benzinga

Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics ↗

November 08, 2023

Biogen Inc. reported $2.53 billion in revenue for the quarter ended September 2023.

Via Talk Markets

US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings ↗

November 08, 2023

Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into...

Via Benzinga

Topics Economy

Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount ↗

November 08, 2023

The company shares in the profits and sales related to Alzheimer's treatment, Leqembi.

Via Investor's Business Daily

3 Biotech Moonshots to Bet on the Future of Health ↗

November 06, 2023

Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.

Via InvestorPlace

Topics Intellectual Property

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Starting at $3.75/week.

Subscribe Today